Free Trial Information
BioCentury | Dec 22, 2014
Company News

Proteo management update

...Inc. (OTCQB:PTEO), Irvine, Calif. Business: Pulmonary, Cardiovascular, Inflammation Hired: Juergen Paal as COO of Proteo’s Proteo Biotech AG...
Read More
BioCentury | May 26, 2014
Company News

Proteo, Biotech Development Corp. deal

Financing company Biotech Development will provide up to €3.5 million ($4.8 million) in funding to support development of Proteo's Elafin tiprelestat in the EU to prevent acute postoperative inflammatory complications after resection of esophageal cancer....
Read More
BioCentury | Aug 13, 2007
Company News

Minapharm, Proteo Biotech deal

...CTPH) in the EU. Further terms were not disclosed. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Proteo Biotech AG...
Read More
BioCentury | Apr 2, 2007
Clinical News

Elafin regulatory update

...proteinase 3 inhibitor, to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPH). Proteo Biotech AG...
Read More
BioCentury | Apr 11, 2005
Company News

Eurogentec, Proteo Biotech deal

...has completed preclinical testing to treat tissue and muscle damage. Eurogentec S.A. , Liege, Belgium Proteo Biotech AG...
Read More
BioCentury | Dec 13, 2004
Company News

Artes Biotechnology GmbH, Proteo Biotech deal

...to reduce tissue damage caused by blood supply deficiencies. Artes Biotechnology GmbH , Duesseldorf, Germany Proteo Biotech AG...
Read More
BioCentury | Jul 19, 2004
Clinical News

Proteo Biotech preclinical data

...recombinant elastase and proteinase 3 inhibitor also reduced tissue damage caused by blood supply deficiencies. Proteo Biotech AG...
Read More
Items per page:
1 - 7 of 7
BioCentury | Dec 22, 2014
Company News

Proteo management update

...Inc. (OTCQB:PTEO), Irvine, Calif. Business: Pulmonary, Cardiovascular, Inflammation Hired: Juergen Paal as COO of Proteo’s Proteo Biotech AG...
Read More
BioCentury | May 26, 2014
Company News

Proteo, Biotech Development Corp. deal

Financing company Biotech Development will provide up to €3.5 million ($4.8 million) in funding to support development of Proteo's Elafin tiprelestat in the EU to prevent acute postoperative inflammatory complications after resection of esophageal cancer....
Read More
BioCentury | Aug 13, 2007
Company News

Minapharm, Proteo Biotech deal

...CTPH) in the EU. Further terms were not disclosed. Minapharm Pharmaceuticals S.A.E. , Cairo, Egypt Proteo Biotech AG...
Read More
BioCentury | Apr 2, 2007
Clinical News

Elafin regulatory update

...proteinase 3 inhibitor, to treat pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPH). Proteo Biotech AG...
Read More
BioCentury | Apr 11, 2005
Company News

Eurogentec, Proteo Biotech deal

...has completed preclinical testing to treat tissue and muscle damage. Eurogentec S.A. , Liege, Belgium Proteo Biotech AG...
Read More
BioCentury | Dec 13, 2004
Company News

Artes Biotechnology GmbH, Proteo Biotech deal

...to reduce tissue damage caused by blood supply deficiencies. Artes Biotechnology GmbH , Duesseldorf, Germany Proteo Biotech AG...
Read More
BioCentury | Jul 19, 2004
Clinical News

Proteo Biotech preclinical data

...recombinant elastase and proteinase 3 inhibitor also reduced tissue damage caused by blood supply deficiencies. Proteo Biotech AG...
Read More
Items per page:
1 - 7 of 7